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Graphical abstract 
Elderly AML patients above 65 years derive similar benefits in overall survival from ASCT 
consolidation in CR1 as AML patients below 65 years. 
 
 
 
 
Highlights 
 
 The outcome of AML patients ≥65 years remains disappointing.  
 Consolidation with autologous transplantation is feasible in elderly AML 
patients. 
 ASCT consolidation in first remission provides longer PFS and OS in elderly 
AML.  
 ASCT provides similar survival benefits in young and elderly AML patients.  
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Abstract 
 
The outcome of AML patients ≥65 years remains disappointing. Current post-
induction strategies for elderly AML patients fit for intensive treatment involve 
additional cycles of chemotherapy or allogeneic transplantation. Consolidation with 
autologous transplantation (ASCT) is poorly studied in these patients. In this single-
center retrospective analysis, we determined survival rates of AML patients ≥65 
years undergoing busulfan/cyclophosphamide conditioning before ASCT in first 
remission between 2007 and 2015. We found elderly AML patients with ASCT to 
have longer progression-free survival (PFS; 16.3 vs. 5.1 months, P=0.0166) and 
overall survival (OS; n.r. vs. 8.2 months; P=0.0255) than elderly AML patients 
without ASCT consolidation. In addition, elderly AML patients undergoing ASCT had 
comparable PFS (P=0.9462) and OS (P=0.7867) as AML patients below 65 years 
receiving ASCT consolidation in CR1. Our data suggest that ASCT is an option in 
elderly fit AML patients who appear to benefit from autologous consolidation similarly 
to younger AML patients. 
 
Keywords: autologous; transplant; elderly; AML; survival. 
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1. Introduction 
 
Acute myeloid leukemia (AML) is predominantly diagnosed in elderly people with a 
median age at diagnosis of 67 years [14]. The outcome of elderly AML patients 
remains disappointing due to the overrepresentation of adverse prognostic factors 
[13]. Even if complete remission rates are achieved in up to 60% after standard 
intensive induction treatment in elderly AML patients, relapses are common leading 
to 2-year survival rates of only 10-20% [11]. Since relapses emerge from residual 
leukemic cells escaping chemotherapy, intensification of AML treatment appears as 
a rational strategy. Accepted modalities to prevent relapse in first complete remission 
in younger AML patients comprise further conventional chemotherapy, allogeneic or 
autologous stem cell transplantation, whereas in elderly AML patients chemotherapy 
consolidation and (less commonly) allogeneic transplantation are applied [13]. 
Autologous stem cell transplantation (ASCT) has become a therapeutic option for 
first-line consolidation in younger adults with AML with good and intermediate risk 
features [15]. In such patients, it offers distinct anti-leukemic effectiveness and 
prolongs survival similar to allogeneic transplantation while avoiding morbidity and 
mortality of graft versus host disease associated with allogeneic transplantation 
[2,17]. However, prospective studies in elderly AML patients comparing 
chemotherapy consolidation with autologous stem cell transplantation (ASCT) or 
allogeneic transplantation are lacking.  
Various retrospective reports have investigated the use of ASCT in elderly AML 
patients with promising results, albeit mostly in highly selected patients [1,5,7,12]. 
Acceptable toxicity and a low rate of transplant-related mortality were reported 
without compromising the rate of relapse, which, irrespective of age, still remains the 
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major cause of treatment failure after ASCT in AML. However, the definition of an 
elderly AML patient has widely varied among the available studies. Whereas earlier 
reports separated such patients as being older than 50 years [1], more recent 
studies defined such patients as older than 60 years [12]. However, an analysis 
investigating the benefit and tolerance of ASCT consolidation specifically in AML 
patients ≥65 years in first remission is currently missing.  
 
2. Patients and methods  
 
2.1 Pretreatment assessments 
In this single-center, retrospective analysis, we investigated busulfan/ 
cyclophosphamide conditioning before ASCT in AML patients ≥65 years in first 
remission treated at the University Hospital Bern, Switzerland between 2007 and 
2015. We compared this cohort to two control groups: (I) AML patients ≥65 years in 
first CR (CR1) after one or two induction cycles without subsequent consolidation 
treatment, and (II) AML patients <65 years undergoing ASCT in CR1 after two cycles 
of induction treatment in the same study period. Patients with acute promyelocytic 
leukemia (APL) were excluded.  
 
2.2 Definitions 
Patients were considered in CR1 if they had a bone marrow blast count of <5% and 
had completed hematologic recovery with platelets above 100 G/L and neutrophils 
above 1.0 G/L. Overall survival was calculated from the date of achieved CR1 to 
death or date of last follow-up. Patients still alive or lost to follow-up were censored 
at the last date when they were known to be alive. Progression-free survival was 
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calculated from date of achieved CR1 to disease progression or relapse, death or 
last follow-up whatever occurred first.  
 
2.3 Statistical analysis 
All reported p-values were from two-tailed Fisher’s or unpaired t tests, and a value of 
P<0.05 was considered as statistically significant. Survival analysis was performed 
using the log-rank method, and analyses were performed using GraphPad Prism® 
Version 7 (GraphPad Software, Inc., La Jolla, CA).  
 
3. Results 
 
3.1. Treatment 
40 AML patients ≥65 years in CR1 after one or two cycles of intensive induction 
chemotherapy were identified. Patients in this period were treated in subsequent 
HOVON/SAKK protocols (HOVON-81, -93, and -103), and 24 of these patients 
received no consolidation treatment as per protocol. 16 Patients ≥65 years 
diagnosed with AML in interval periods without an active protocol and considered to 
be fit for consolidation treatment underwent ASCT for consolidation of first remission. 
Induction consisted in two cycles of chemotherapy in all patients, with cytarabine and 
daunorubicin in cycle 1, and six days of 1000mg/m2 of cytarabine every 12 hours in 
cycle 2, respectively. Conditioning treatment before ASCT consisted of busulfan 
4mg/kg/day p.o. for four days and cyclophosphamide 60mg/kg/day i.v. for two days.  
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3.2 Patient characteristics 
Baseline characteristics including cytogenetic and molecular risk groups at diagnosis 
of AML patients ≥65 years with and without ASCT are summarized in Table I. In 
elderly AML patients with ASCT, we observed more favorable risk patients (31.3% 
vs. 16.7%) and less adverse risk patients (12.5% vs. 37.5%) than in elderly patients 
without ASCT; however, these differences were not significant (P=0.4414 and 
P=0.1478).  
 
3.3 Survival and efficacy 
Elderly AML patients with ASCT consolidation achieved longer progression-free 
survival (PFS; 16.3 vs. 5.1 months; P=0.0166) and overall survival (OS; n.r. vs. 8.2 
months; P=0.0255) than elderly patients without ASCT consolidation (Figure 1). At 
24 months after achievement of CR1, PFS rates were 48.2% in the ASCT cohort and 
15.6% in the non-ASCT group. OS rates were 60.6% in the ASCT cohort compared 
to 29.8% in patients without ASCT. Early mortality in the first 100 days after 
achievement of CR1 was lower in the ASCT group (6% vs. 20.8%); however, this 
difference was not significant (P=0.3752), nor was the difference in the rates of 
relapse (43.8% vs. 66.6%, P=0.1991).   
In addition, we compared the outcome after ASCT consolidation of AML patients ≥65 
years to patients <65 years with ASCT in CR1. (Table I). We identified 49 patients 
younger than 65 years, who underwent ASCT in this same study period at our 
institution. Baseline characteristics between these two groups were balanced apart 
from CEBPA mutations, which were more frequently present in elderly patients (0% 
vs. 18.8%, P=0.0128). We observed no differences in PFS (16.3 vs. 30.8 months, 
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P=0.9462) and OS (n.r. vs. 56.4 months, P=0.7867; Figure 2). At 24 months after 
ASCT, PFS and OS rates were 48.2% and 60.2% in the elderly, and 59.8% and 
50.0% in the younger cohort. We observed no treatment-related deaths in both 
groups, and all early deaths (6.2% in elderly vs. 0% in younger AML patients, 
P=0.2462) were due to disease progression. The median time from diagnosis to 
ASCT was similar in younger and elderly patients (105 and 123 days, respectively; 
P=0.9138).  
 
3.4 Subgroup analysis 
We further compared survival between different cytogenetic ELN risk groups [11]. 
Survival of all patients undergoing ASCT stratified according to the four different 
cytogenetic risk groups are depicted in Figure 3A. We identified no survival 
differences between the three cohorts favorable, Intermediate-I and adverse groups 
(P=0.1918, P=0.6491, and P=0.1291, respectively). Noteworthy, the very small 
group of intermediate-II patients ≥65 years with ASCT (n=4) had better survival rates 
than elderly patients without ASCT (n=4) and also than younger patients undergoing 
ASCT (n=9; P=0.0214; data not shown). Finally, the various ELN risk groups showed 
different survival rates (Figure 3B) in younger AML patients undergoing ASCT 
whereas the subgroups in our cohort of elderly AML patients were too small to allow 
such conclusions (data not shown).  
 
4. Discussion 
 
Our data suggest that fit AML patients ≥65 years may tolerate ASCT consolidation in 
CR1 and equally benefit from such treatment as young AML patients in CR1. 
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Obvious limitations of this study are its retrospective, single center and non-
randomized design inevitably leading to a relevant selection bias. Accordingly, 
physicians may have tended to offer ASCT more likely to patients with favorable risk 
features, good tolerance of induction treatment, and achievement of early remission 
(already after one induction cycle). As one of the consequences, our study identified 
a higher percentage of patients with adverse cytogenetic abnormalities in the 
subgroup of elderly patients without ASCT consolidation as compared to elderly 
patients with ASCT consolidation, thereby affecting the comparison between these 
two groups. 
The selection process of patients is considerable, since we have diagnosed a total of 
78 patients aged ≥65 years with AML in the study period, and 55 of these patients 
ultimately underwent intensive chemotherapy induction treatment. We observed that 
40 of these 55 patients achieved CR1, and only 16 (29%) of all elderly AML patients 
were finally treated with ASCT consolidation. Whereas these rates are comparable 
to previous studies, they illustrate the significant selection bias involved in such 
retrospective studies [12].  
To the best of our knowledge, this is the largest study so far reporting on the use of 
ASCT after busulfan/ cyclophosphamide conditioning in AML patients ≥65 years and 
the comparison to the same age cohort of AML patients not receiving ASCT 
consolidation. Our data support a concept that ASCT is feasible in selected elderly 
AML patients considered to be fit for intensive treatment. Elderly AML patients 
receiving ASCT in CR1 appear to benefit from both reduced risk of relapse and 
longer overall survival, with a remarkable overall survival rate of 60.6% 24 months 
after achievement of CR1. The rates of overall and progression-free survival were 
comparable with previous reports [5]. However, our data challenge earlier 
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observations of longer PFS and OS in patients younger than 50 years compared to 
those of patients older than 50 years [1]. The assessment of the benefit of ASCT in 
elderly AML patients for specific cytogenetic risk groups is limited by the small 
number of patients in these groups in our cohort. However, differing outcome rates in 
various risk groups were observed in our somewhat larger group of younger patients 
undergoing ASCT (n=49) suggesting that the benefit of ASCT consolidation is limited 
to favorable risk groups of AML. 
A prerequisite of ASCT is the successful preceding collection of a sufficient number 
of autologous stem cells obtained usually following hematologic recovery after the 
second induction cycle and after confirmed achievement of complete remission. 
Differences in stem cell mobilization and collection success rates between younger 
and elderly AML patients are rarely reported. In a retrospective analysis including 40 
patients, Ferrara et al. demonstrated similar CD34 yield and successful mobilization 
rates in patients above and below 60 years and concluded that age does not 
significantly affect mobilization and collection of peripheral stem cells [4]. However, 
others have reported reduced proliferative potential of stem cells in elderly stem cell 
donors [10]. 
Compared to chemotherapy consolidation, ASCT provides timely hematologic 
recovery, thereby reducing the probability of infectious or hemorrhagic complications 
[8,9]. Reduced intensity conditioning (RIC) with allogeneic stem cell transplantation 
has also been investigated as a consolidation strategy in elderly AML patients. In an 
analysis of RIC and allogeneic stem cell transplantation in patients 60 years and 
older, similar OS and PFS rates after 24 months were observed as in our cohort; 
however, extensive chronic GvHD was observed in 62.5% of these patients [6]. 
Therefore, in elderly patients with appropriate risk profile consolidation with ASCT 
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seems to have similar efficacy as RIC allogeneic transplantation while avoiding 
GvHD. Moreover, graft failure in ASCT is a rare event. 
Our report suggests that ASCT can be considered an effective and safe 
consolidation option for AML patients above 65 years. Age emerges as an unreliable 
parameter for an individual’s physical condition, and biological age tends to vary 
considerably among people of the same age cohort [13]. Although age is (among 
others) an important adverse prognostic factor in AML, it fails to explain as a single 
parameter the poor outcome of elderly AML patients [16]. Accordingly, the 
overrepresentation of adverse cytogenetic abnormalities, poor performance status 
and comorbidities also contribute to the poor outcome of elderly AML patients. Our 
data indicate that age per se should not prevent physicians to propose ASCT to the 
steadily increasing proportion of AML patients ≥65 years for consolidation of first 
complete remission. However, the selection of appropriate patients remains a 
challenging task, but our data suggest that the benefit of ASCT consolidation in AML 
patients ≥65 years merits prospective evaluation.  
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Figure legends 
 
Figure 1:  
Kaplan-Meyer survival curves comparing survival of AML patients ≥65 years 
undergoing ASCT in first CR (solid line) and AML patients ≥65 years without ASCT 
in first CR (spotted line). A: progression free survival; B: overall survival.  
 
Figure 2:  
Kaplan-Meyer survival curves comparing survival of AML patients ≥65 years 
undergoing ASCT in first CR (solid line) and AML patients <65 years undergoing 
ASCT consolidation (spotted line). A: progression free survival; B: overall survival. 
 
Figure 3:  
Kaplan-Meyer survival curves comparing survival of AML patients according to 
cytogenetic risk group. A: all patients; B: patients <65y undergoing ASCT.  
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Figure 2 
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Table legends 
 
Table 1:  
Clinical characteristics, outcome and univariate analysis in elderly AML patients with 
ASCT in CR1 compared to elderly AML patients without ASCT in CR1 and younger 
patients with ASCT in CR1. 
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Table I: Clinical characteristics, outcome and univariate analysis in elderly (≥ 65 years ) AML patients with ASCT in CR1 compared  
               to elderly AML patients without ASCT in CR1 and to younger (< 65 years) patients with ASCT in CR1. 
           
 
elderly pts. with 
ASCT (n=16) % 
elderly pts. without 
ASCT (n=24) % p  s 
young pts. with 
ASCT (n=49) % p s 
           
Baseline characteristics                     
           
Age, median (range) 66.0 (64.2-72.5) 
 
68.7 (64.1-74.4) 
 
0.1628 ns 51.1 (19.6-63.5) 
 
<0.0001 **** 
Gender, male 8 50.0 14 58.3 0.7481 ns 27 55.1 0.7782 ns 
Hemoglobin (g/L) 96.5 (59.0-133.0) 
 
89.5 (38.0-119.0) 
 
0.1970 ns 88.0 (43.0-151.0) 
 
0.6344 ns 
WBC† (G/L) 11.8 (2.4-58.8) 
 
2.8 (0.7-87.1) 
 
0.5440 ns 9.8 (0.9-240.7) 
 
0.2608 ns 
ANC‡ (G/L) 1.1 (0.1-10.0) 
 
0.5 (0.1-18.3) 
 
0.8067 ns 1.5 (0.0-50.2) 
 
0.3883 ns 
Peripheral blasts (%) 39.5 (1.0-90.0) 
 
6.8 (0-89.0) 
 
0.0199 
 
38.8 (0.0-96.0) 
 
0.8102 ns 
Bone marrow blasts (%) 67.8 (20.0-95.0) 
 
37.5 (5.0-90.0) 
 
0.1249 ns 65.0 (0.0-95.0) 
 
0.4986 ns 
Platelets (G/L) 62.0 (18-301) 
 
119.5 (13.0-260.0) 
 
0.3598 ns 66.0 (7.0-608.0) 
 
0.7577 ns 
LDH (IU/L) 593.5 (288.0-2514.0) 
 
544.5 (198.0-2323.0) 
 
0.2131 ns 755.5 (156.0-8352.0) 
 
0.2877 ns 
           
FAB 16 100 24 100 
  
49 100 
  
M0 3 18.8 8 33.3 0.4732 ns 5 10.2 0.3952 ns 
M1 5 31.3 5 20.8 0.4824 ns 8 16.3 0.2791 ns 
M2 3 18.8 4 16.7 1.0000 ns 17 34.7 1.0000 ns 
M4 1 6.3 0 0.0 - - 10 20.4 0.4000 ns 
M5 2 12.5 4 16.7 1.0000 ns 6 12.2 1.0000 ns 
M6 0 0.0 2 8.3 - - 1 2.0 - - 
M7 0 0.0 1 4.2 - - 0 0.0 - - 
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sec. from MDS/th-related 1 6.3 0 0.0 - - 0 0.0 - - 
ND§ 1 6.3 0 0.0 - - 2 4.1 - - 
           
Adverse risk 2 12.5 9 37.5 0.1478 ns 4 8.2 0.6306 ns 
-5 or del(5q) 0 0.0 2 8.3 - - 0 0.0 - - 
t(v;11)(v;q23) 0 0.0 0 0.0 - - 1 2.1 - ns 
Complex karyotype 2 12.5 7 29.1 0.2717 ns 3 6.1 0.5896 ns 
Intermediate-I 5 31.3 7 29.1 1.0000 ns 15 30.6 1.0000 ns 
NPM1mut+FLT3-ITD 3 18.8 2 8.3 0.3725 ns 5 10.2 0.3952 ns 
NPM1wt+FLT3-ITD 0 0.0 1 4.2 - - 1 2.0 - - 
Normal karyotype 2 12.5 4 16.7 1.0000 ns 9 18.4 0.7178 ns 
Intermediate-II 4 25.0 4 16.7 0.6905 ns 9 18.4 0.6905 ns 
not otherwise classified 4 25.0 4 16.7 0.6905 ns 9 18.4 0.6905 ns 
Favorable 5 31.3 4 16.7 0.4414 ns 21 42.9 0.5590 ns 
t(8;21) 1 6.3 1 4.2 - - 8 16.3 0.4326 ns 
inv(16) 0 0.0 0 0.0 - - 3 6.1 0.5692 ns 
NPM1mut+FLT3wt 1 6.3 0 0.0 - - 10 20.4 0.2677 ns 
CEBPA mut 3 18.8 3 12.5 0.6678 ns 0 0.0 0.0128 * 
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Outcome                     
           
Progression-free survival  
          
(months, median) 16.3 
 
5.1 
 
0.0166 * 30.8 
 
0.9462 ns 
Overall survival  
          
(months, median) not reached yet 
 
8.2 
 
0.0255 * 56.4 
 
0.7867 ns 
Early death  
          
(100 days) 1 6.3 5 20.8 0.3725 ns 0 0.0 0.2462 ns 
Follow up  
          
(months, median) 44.6 
 
36.5 
 
0.9974 ns 43.4 
 
0.3391 ns 
           
Univariate Analysis                     
           
Progression-free survival 
          
ASCT yes 
  
1.000 (reference) 
 
0.0166 * 1.000 (reference) 
 
0.9462 ns 
ASCT no 
  
2.598 (1.238-5.449) 
   
1.027 (0.465-2.274) 
   
Overall survival 
          
ASCT yes 
  
1.000 (reference) 
 
0.0255 * 1.000 (reference) 
 
0.7867 ns 
ASCT no 
  
2.713 (1.217-6.044) 
   
1.132 (0.444-2.889) 
   
           
          
            
P: comparison to elderly patients with ASCT; *autologous stem cell transplantation; †white blood cells; ‡absolute neutrophil count; §no data available.    
 
                                                                 
 
